SciClone ($SCLN) Reports Financial Results for the Fourth Quarter and Year 2011 and Outlook for 2012

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is a revenue-generating, profitable, China-centric specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders.

SciClone Pharmaceuticals has reported its financial results for the fourth quarter and year ended December 31, 2011. Reported revenues increased by 75% in the fourth quarter compared to revenues in the prior year. Overall, revenues increased 57% for the calendar year when compared to the previous calendar year. This growth in revenue is largely due to the expansion of the ZADAXIN® business in China and SciClone’s acquisition of NovaMed Pharmaceuticals, Inc. in April, 2011. 

Friedhelm Blobel, PhD., SciClone President and Chief Executive Officer, commented, 

"SciClone delivered solid financial performances in the fourth quarter and full year of 2011, driven by the continued strong revenue growth of ZADAXIN, Depakine® and our other marketed products in China, and managed by the well coordinated efforts of our integrated SciClone and NovaMed sales and marketing teams. We believe that 2011 was a year of significant strategic advancement for our Company marked by important accomplishments that strengthen our business, market position and reputation. Prime among these was the transition from a typical biotech to a China-focused specialty pharmaceutical company."

He continued, 

"With the successful integration of NovaMed, we have largely completed this transition. And we have significantly expanded our portfolio of marketed and pipeline products and expanded our commercial capability. Our 23% annual ZADAXIN revenue growth, which exceeds the growth rate of the China pharmaceuticals market, and the overall strengthening of our China platform, position SciClone in the top-performing echelon of multi-national companies in this important and growing market. We are confident that we have put the right strategies, management talent and infrastructure in place to continue to capitalize on the significant growth opportunities inherent in the China market. We look forward to continuing this impressive growth in 2012."

Read the full press release at investor.sciclone.com.